Elicio Therapeutics, Inc.
ELI-002 7P
metastatic mKRAS pancreatic cancer
Resolved
7days ago
Advisory committee · ~ Jun 30, 2026 estimated
What's at stake
An FDA advisory committee reviews ELI-002 7P for metastatic mKRAS pancreatic cancer around ~ Jun 30, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“Engage with FDA: End-of-Phase 2 Meeting Align with FDA on Phase 3 design & regulatory strategy: ELI-002 7P in R0 resected adjuvant mKRAS PDAC”